Canadian pharmaceuticals company Valeant Pharmaceuticals International, Inc. (NYSE:VRX) recently announced that it has entered into a definitive agreement to acquire private eye care company, Eyetech, Inc., signaling management’s increasing interest to enter into the ophthalmic space. The acquisition will add Eyetech’s drug Macugen to Valeant Pharma’s ophthalmic portfolio.
Macugen is marketed in the US for the treatment of wet age-related macular degeneration (AMD) by Eyetech. However, … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards